Physician profile
Evan Choi
NPI 1023351855
$2,495.33
in general payments reported to CMS, 2019-2025
20 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $360 · 2021: $149 · 2022: $293 · 2023: $207 · 2024: $536 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $594.05 | 2019-2022 | |
| Astellas Pharma US INC | $231.00 | 2019-2022 | |
| Amgen INC. | $216.47 | 2022-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $163.27 | 2024-2025 | Verquvo, Gardasil 9, Capvaxive |
| Medtronic, INC. | $162.57 | 2025 | Osteocool Rf Ablation System |
| Inari Medical, INC. | $136.79 | 2021 | |
| United Therapeutics Corporation | $123.08 | 2025 | Tyvaso |
| Impulse Dynamics (USA) INC. | $120.70 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $103.46 | 2019 | |
| Medtronic Vascular, INC. | $102.90 | 2019 | |
| Daiichi Sankyo INC. | $101.79 | 2024 | Injectafer |
| Novo Nordisk INC | $97.74 | 2024 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.35 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $65.04 | 2023-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $57.31 | 2021-2025 | Watchman Flx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53.39 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.50 | 2024-2025 | Lifevest |
| Lilly USA, LLC | $24.28 | 2024 | Mounjaro |
| Scpharmaceuticals INC. | $21.94 | 2025 | |
| Lantheus Medical Imaging, INC. | $18.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.